MVM raises $233M life sciences fund

MVM Life Science Partners has closed a $233 million fourth fund to invest in technologies, therapeutics, medical devices and healthcare IT companies. The London-based firm expects to do deals ranging from early stage to public companies. It will invest about $15 million to $30 million per portfolio company. Its med tech investments have included surgical wound closure company ZipLine Medical, noninvasive hemodynamic monitoring company Cheetah Medical and AAA stent graft manufacturer Lombard Medical Technologies ($EVAR). More

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.